Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2

Cancer Research

Volumn 65, Issue 16, 2005, Pages 7320-7327

  Titus, Brian ^a   Frierson Jr , Henry F ^a   Conaway, Mark ^b   Ching, Keith ^c   Guise, Theresa ^a   Chirgwin, John ^a   Hampton, Garret ^c   Theodorescu, Dan ^a,d  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^d UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRASENTAN; DNA; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; GENE IDENTIFICATION; GENE REPRESSION; HUMAN; HUMAN CELL; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RHOGD12 GENE; TUMOR SUPPRESSOR GENE; UPREGULATION;

ANIMALS; CELL LINE, TUMOR; DOWN-REGULATION; ENDOTHELIN-1; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GUANINE NUCLEOTIDE DISSOCIATION INHIBITORS; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 23844468385     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1403     Document Type: Article

References (37)

1. Sengelov L, Kamby C, von der Maase H. Pattern of metastases in relation to characteristics of primary tumor and treatment in patients with disseminated urothelial carcinoma. J Urol 1996;155:111-4.
2. Dinney CP, McConkey DJ, Millikan RE, et al. Focus on bladder cancer. Cancer Cell 2004;6:111-6.
3. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994;79:185-8.
4. Gildea JJ, Seraj MJ, Oxford G, et al. RhoGDH is an invasion and metastasis suppressor gene in human cancer. Cancer Res 2002;62:6418-23.
5. Theodorescu D, Sapinoso LM, Conaway MR, Oxford G, Hampton GM, Frierson HF Jr. Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin Cancer Res 2004;10:3800-6.
6. Welch DR. Microarrays bring new insights into understanding of breast cancer metastasis to bone. Breast Cancer Res 2004;6:61-4.
7. Steeg PS. Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 2003;3:55-63.
8. Jain N, Thatte J, Braciale T, Ley K, O'Connell M, Lee JK. Local-pooled-error test for identifying differentially expressed genes with a small number of replicated microarrays. Bioinformatics 2003;19:1945-51.
9. Zhong S, Li C, Wong WH. ChipInfo: software for extracting gene annotation and gene ontology information for microarray analysis. Nucleic Acids Res 2003;31:3483-6.
10. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A 2001;98:31-6.
11. Welsh JB, Sapinoso LM, Kern SG, et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A 2003;100:3410-5.
12. Gildea JJ, Golden WL, Harding MA, Theodorescu D. Genetic and phenotypic changes associated with the acquisition of tumorigenicity in human bladder cancer. Genes Chromosomes Cancer 2000;27:252-63.
13. Seraj MJ, Harding MA, Gildea JJ, Welch DR, Theodorescu D. The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines. Clin Exp Metastasis 2000;18:519-25.
14. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003;3:110-6.
15. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666-75.
16. Theodorescu D, Cornil I, Sheehan C, Man S, Kerbel RS. Dominance of metastatically competent cells in primary murine breast neoplasms is necessary for distant metastatic spread. Int J Cancer 1991;47:118-23.
17. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:49-54.
18. Masaki T. Historical review: endothelin. Trends Pharmacol Sci 2004;25:219-24.
19. Foschi M, Chari S, Dunn MJ, Sorokin A. Biphasic activation of p21ras by endothelin-1 sequentially activates the ERK cascade and phosphatidylinositol 3-kinase. EMBO J 1997;16:6439-51.
20. Simler NR, Brenchley PE, Horrocks AW, Greaves SM, Hasleton PS, Egan JJ. Angiogenic cytokines in patients with idiopathic interstitial pneumonia. Thorax 2004;59:581-5.
21. Varda-Bloom N, Shaish A, Gonen A, et al. Tissue-specific gene therapy directed to tumor angiogenesis. Gene Ther 2001;8:819-27.
22. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001;98:10314-9.
23. Seville LL, Shah N, Westwell AD, Chan WC. Modulation of pRB/E2F functions in the regulation of cell cycle and in cancer. Curr Cancer Drug Targets 2005;5:159-70.
24. Fagan KA, McMurtry IF, Rodman DM. Role of endothelin-1 in lung disease. Respir Res 2001;2:90-101.
25. Spinella F, Rosano L, Di Castro V, Natali PG, Bagnato A. Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1α in ovarian carcinoma cells. J Biol Chem 2002;277:27850-5.
26. Okuda Y, Tsurumaru K, Suzuki S, et al. Hypoxia and endothelin-1 induce VEGF production in human vascular smooth muscle cells. Life Sci 1998;63:477-84.
27. Chirgwin JM, Guise TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr 2000;10:159-78.
28. Benigni A, Perico N, Remuzzi G. The potential of endothelin antagonism as a therapeutic approach. Expert Opin Investig Drugs 2004;13:1419-35.
29. Zonnenberg BA, Groenewegen G, Janus TJ, et al. Phase 1 dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer. Clin Cancer Res 2003;9:2965-72.
30. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21:679-89.
31. Oxford G, Theodorescu D. The role of Ras superfamily proteins in bladder cancer progression. J Urol 2003; 170:1987-93.
32. Hernandez-Perera O, Perez-Sala D, Soria E, Lamas S. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res 2000;87:616-22.
33. Kamai T, Kawakami S, Koga F, et al. RhoA is associated with invasion and lymph node metastasis in upper urinary tract cancer. BJU Int 2003;91:234-8.
34. Kamai T, Tsujii T, Arai K, et al. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res 2003;9:2632-41.
35. DiSanto ME, Wein AJ, Chacko S. Lower urinary tract physiology and pharmacology. Curr Urol Rep 2000;1:227-34.
36. Gildea JJ, Herlevsen M, Harding MA, et al. PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity. Oncogene 2004;23:6788-97.
37. Theodorescu D, Cornil I, Fernandez BJ, Kerbel RS. Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma Proc Natl Acad Sci U S A 1990;87:9047-51.